Pathophysiological consequences and benefits of HFE mutations: 20 years of research

Haematologica

Volumn 102, Issue 5, 2017, Pages 809-817

  Hollerer, Ina ^a,b,c   Bachmann, André ^d   Muckenthaler, Martina U ^a,c  

^a Molecular Medicine Partnership Unit (MMPU)   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Private Practice   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CERULOPLASMIN; FERROPORTIN; HAPTOGLOBIN; HEMOCHROMATOSIS PROTEIN; HEMOJUVELIN; HEPCIDIN; IRON; LIVER ENZYME; TRANSFERRIN;

DNA POLYMORPHISM; ETHNICITY; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMOCHROMATOSIS; HEMOCHROMATOSIS GENE; HETEROZYGOSITY; HUMAN; HYPERPIGMENTATION; IRON METABOLISM; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOSS OF FUNCTION MUTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PENETRANCE; PHENOTYPE; PREVALENCE; REVIEW; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; GENETICS; METABOLISM; MUTATION; PARKINSON DISEASE; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; GENETIC PREDISPOSITION TO DISEASE; HEMOCHROMATOSIS; HEMOCHROMATOSIS PROTEIN; HUMANS; IRON; MUTATION; PARKINSON DISEASE;

EID: 85018942617     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.160432     Document Type: Review

References (129)

1. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell. 2017;168(3):344-361.
2. Yun S, Vincelette ND. Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis. Crit Rev Oncol Hematol. 2015;95(1):12-25.
3. Gallego CJ, Burt A, Sundaresan AS, et al. Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network. Am J Hum Genet. 2015;97(4):512-520.
4. Barton JC. Hemochromatosis and iron overload: from bench to clinic. Am J Med Sci. 2013;346(5):403-412.
5. Trousseau A. Glycosurie; diabete sucre. Clinique Med de l'Hotel de Paris. 1865;2: 663-698.
6. Hanot V, Chauffard A. [Cirrhose hyper-trophique pigmentaire dans le diabète sucré]. Rev Med. 1882;2:385-403.
7. Troisier M. [Diabète sucré]. Bull Soc Anatomique Paris. 1871;44:231-235.
8. von Recklinghausen FD. [Uber Haemochromatose. Taggeblatt der 62 Versammlung deutscher Naturforscher and Aerzte in Heidelberg]. 1889:324-325.
9. Sheldon JH. Haemochromatosis London: Oxford University Press, 1935.
10. Simon M, Pawlotsky Y, Bourel M, Fauchet R, Genetet B. [Idiopathic hemochromatosis associated with HL-A 3 tissular antigen]. Nouv Presse Med. 1975;4(19):1432.
11. Laufberger V. [Sur la cristallisation de la fer-ritine]. Soc Chim Biol. 1937.
12. Schade AL, Caroline L. An iron-binding component in human blood plasma. Science. 1946;104(2702):340.
13. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):399-408.
14. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004; 36(1):77-82.
15. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33(1):21-22.
16. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25(1):14-15.
17. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001; 108(4):619-623.
18. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001;28(3):213-214.
19. Seckington R, Powell L. HFE-Associated Hereditary Hemochromatosis. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., eds. GeneReviews(R). Seattle (WA), 1993.
20. Porto G, Brissot P, Swinkels DW, et al. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet. 2016;24(4):479-495.
21. Garbowski MW, Ma YM, Fucharoen S, Srichairatanakool S, Hider R, Porter JB. Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay. Transl Res. 2016;177:19-30.
22. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012;1820(3):403-410.
23. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769-1778.
24. European Association For The Study Of The L. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22.
25. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem. 1997;272(22):14025-14028.
26. Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA. 1997;94(23):12384-12389.
27. Giannetti AM, Bjorkman PJ. HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface. J Biol Chem. 2004;279(24):25866-25875.
28. West AP Jr, Giannetti AM, Herr AB, et al. Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. J Mol Biol. 2001;313(2):385-397.
29. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006;281(39):28494-28498.
30. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482-487.
31. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4):478-481.
32. Daher R, Kannengiesser C, Houamel D, et al. Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. Gastroenterology. 2016; 150(3):672-683 e4.
33. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38(5):531-539.
34. Steinbicker AU, Bartnikas TB, Lohmeyer LK, et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011;118(15):4224-4230.
35. Mayeur C, Leyton PA, Kolodziej SA, Yu B, Bloch KD. BMP type II receptors have redundant roles in the regulation of hepatic hepcidin gene expression and iron metabolism. Blood. 2014;124(13):2116-2123.
36. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005;2(6):399-409.
37. Latour C, Besson-Fournier C, Meynard D, et al. Differing impact of the deletion of hemochromatosis-associated molecules HFE and transferrin receptor-2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin. Hepatology. 2016;63(1):126-137.
38. Wu XG, Wang Y, Wu Q, et al. HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression. Blood. 2014;124(8):1335-1343.
39. D'Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012;57(5):1052-1060.
40. Ryan JD, Ryan E, Fabre A, Lawless MW, Crowe J. Defective bone morphogenic protein signaling underlies hepcidin deficiency in HFE hereditary hemochromatosis. Hepatology. 2010;52(4):1266-1273.
41. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002;122(3):646-651.
42. Holmstrom P, Marmur J, Eggertsen G, Gafvels M, Stal P. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut. 2002;51(5):723-730.
43. Ramakrishna R, Gupta S, Sarathy K, Bowen A. Phenotypic and clinical manifestations of compound heterozygous genetic haemochromatosis (CHGH): a non-invasive approach to clinical management. Intern Med J. 2013;43(3):254-261.
44. Gurrin LC, Bertalli NA, Dalton GW, et al. HFE C282Y/H63D Compound Heterozygotes Are at Low Risk of Hemochromatosis-Related Morbidity. Hepatology. 2009;50(1):94-101.
45. Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozy-gosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol. 2006;4(11):1403-1410.
46. Vecchi C, Montosi G, Pietrangelo A. Huh-7: a human "hemochromatotic" cell line. Hepatology. 2010;51(2):654-659.
47. Takano A, Niimi H, Atarashi Y, et al. A novel Y231del mutation of HFE in hereditary haemochromatosis provides in vivo evidence that the Huh-7 is a human haemochromatotic cell line. Liver Int. 2011;31(10):1593-1597.
48. Le Gac G, Gourlaouen I, Ronsin C, et al. Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype. Blood. 2008;112(13):5238-5240.
49. Pelucchi S, Mariani R, Bertola F, Arosio C, Piperno A. Homozygous deletion of HFE: the Sardinian hemochromatosis? Blood. 2009;113(16):3886.
50. Cezard C, Rabbind Singh A, Le Gac G, Gourlaouen I, Ferec C, Rochette J. Phenotypic expression of a novel C282Y/R226G compound heterozygous state in HFE hemochromatosis: molecular dynamics and biochemical studies. Blood Cells Mol Dis. 2014;52(1):27-34.
51. Piperno A, Arosio C, Fossati L, et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology. 2000; 119(2):441-445.
52. Wallace DF, Subramaniam VN. Non-HFE haemochromatosis. World J Gastroenterol. 2007;13(35):4690-4698.
53. Santos PC, Dinardo CL, Cancado RD, Schettert IT, Krieger JE, Pereira AC. Non-HFE hemochromatosis. Rev Bras Hematol Hemoter. 2012;34(4):311-316.
54. Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood. 2001;97(9):2555-2560.
55. Detivaud L, Island ML, Jouanolle AM, et al. Ferroportin Diseases: Functional Studies, a Link Between Genetic and Clinical Phenotype. Hum Mutat. 2013;34(11):1529-1536.
56. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood. 2005;105(10):4096-4102.
57. Pietrangelo A. Genetics, Genetic Testing, and Management of Hemochromatosis: 15 Years Since Hepcidin. Gastroenterology. 2015;149(5):1240-1251.e4.
58. Coppin H, Bensaid M, Fruchon S, Borot N, Blanche H, Roth MP. Longevity and carrying the C282Y mutation for haemochromatosis on the HFE gene: case control study of 492 French centenarians. BMJ. 2003;327 (7407):132-133.
59. Allen KJ, Bertalli NA, Osborne NJ, et al. HFE Cys282Tyr Homozygotes With Serum Ferritin Concentrations Below 1000 mu g/L Are at Low Risk of Hemochromatosis. Hepatology. 2010;52(3):925-933.
60. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343.
61. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221-230.
62. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33(3):647-651.
63. Gannon PO, Medelci S, Le Page C, et al. Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer. 2011;128(10):2326-2334.
64. Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51(4):1311-1318.
65. Shaheen NJ, Silverman LM, Keku T, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95(2):154-159.
66. Syrjakoski K, Fredriksson H, Ikonen T, et al. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients. Int J Cancer. 2006;118(2):518-520.
67. Ashrafian H. Hepcidin: the missing link between hemochromatosis and infections. Infect Immun. 2003;71(12):6693-6700.
68. Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis. 2007;11(6):482-487.
69. Arezes J, Jung G, Gabayan V, et al. Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell Host Microbe. 2015;17(1):47-57.
70. Wang HZ, He YX, Yang CJ, Zhou W, Zou CG. Hepcidin Is Regulated during Blood-Stage Malaria and Plays a Protective Role in Malaria Infection. J Immunol. 2011; 187(12):6410-6416.
71. Benesova K, Vujic Spasic M, Schaefer SM, et al. Hfe deficiency impairs pulmonary neutrophil recruitment in response to inflammation. PloS One. 2012;7(6):e39363.
72. Kanwar P, Kowdley KV. Diagnosis and treatment of hereditary hemochromatosis: an update. Expert Rev Gastroenterol Hepatol. 2013;7(6):517-530.
73. Brissot P. Optimizing the diagnosis and the treatment of iron overload diseases. Expert Rev Gastroenterol Hepatol. 2016;10(3):359-370.
74. Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-relat-ed hereditary hemochromatosis. Hepatology. 2010;52(5):1671-1779.
75. Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012;120(18): 3829-3836.
76. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388 (10045):706-716.
77. Liver EAFTSOT. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3-22.
78. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Worwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet. 2004;115(4):269-279.
79. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4(2):183-198.
80. Barton JC, Wiener HW, Acton RT, Go RC. HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol Dis. 2005;34(1):38-47.
81. Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet. 2003;34(1):102-107.
82. Levy JE, Montross LK, Andrews NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest. 2000;105(9):1209-1216.
83. Piperno A, Sampietro M, Pietrangelo A, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology. 1998;114(5):996-1002.
84. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122(2):281-289.
85. Cade JE, Moreton JA, O'Hara B, et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr. 2005;82(4):813-820.
86. Benyamin B, Esko T, Ried JS, et al. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun. 2015;6:6542.
87. Benyamin B, Ferreira MAR, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet. 2009;41(11):1173-1175.
88. de Tayrac M, Roth MP, Jouanolle AM, et al. Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis. J Hepatol. 2015;62(3):664-672.
89. Milet J, Dehais V, Bourgain C, et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet. 2007;81(4):799-807.
90. McLaren CE, Emond MJ, Subramaniam VN, et al. Exome sequencing in HFE C282Y homozygous men with extreme pheno-types identifies a GNPAT variant associated with severe iron overload. Hepatology. 2015;62(2):429-439.
91. Pelucchi S, Mariani R, Calza S, et al. CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematol-Hematol J. 2012;97(12):1818-1825.
92. Stickel F, Buch S, Zoller H, et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet. 2014;23(14):3883-3890.
93. Barton JC, LaFreniere SA, Leiendecker-Foster C, et al. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. Am J Hematol. 2009;84(11):710-714.
94. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Blood. 2003;102(11): 758a-758a.
95. Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005; 128(2):470-479.
96. Biasiotto G, Belloli S, Ruggeri G, et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem. 2003;49(12):1981-1988.
97. Tolosano E, Fagoonee S, Garuti C, et al. Haptoglobin modifies the hemochromatosis phenotype in mice. Blood. 2005;105(8): 3353-3355.
98. Gouya L, Muzeau F, Robreau AM, et al. Genetic study of variation in normal mouse iron homeostasis reveals ceruloplasmin as an HFE-hemochromatosis modifier gene. Gastroenterology. 2007;132(2):679-686.
99. Cairo G, Conte D, Bianchi L, Fraquelli M, Recalcati S. Reduced serum ceruloplasmin levels in hereditary haemochromatosis. Br J Haematol. 2001;114(1):226-229.
100. Naugler C. Hemochromatosis: a Neolithic adaptation to cereal grain diets. Med Hypotheses. 2008;70(3):691-692.
101. Olakanmi O, Schlesinger LS, Britigan BE. Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within human macrophages. J Leukoc Biol. 2007;81(1):195-204.
102. Ben-Othman R, Flannery AR, Miguel DC, Ward DM, Kaplan J, Andrews NW. Leishmania-Mediated Inhibition of Iron Export Promotes Parasite Replication in Macrophages. Plos Pathog. 2014;10(1): e1003901.
103. Paradkar PN, De Domenico I, Durchfort N, Zohn I, Kaplan J, Ward DM. Iron depletion limits intracellular bacterial growth in macrophages. Blood. 2008;112(3):866-874.
104. Nairz M, Theurl I, Ludwiczek S, et al. The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol. 2007; 9(9):2126-2140.
105. Leitner DF, Stoute JA, Landmesser M, Neely E, Connor JR. The HFE genotype and a formulated diet controlling for iron status attenuate experimental cerebral malaria in mice. Int J Parasitol. 2015;45(12):797-808.
106. Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. 2008;181(4):2723-2731.
107. Vinchi F, Costa da Silva M, Ingoglia G, et al. Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood. 2016;127(4):473-486.
108. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, pre-menopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222-3227.
109. Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. 2012;184(11):1247-1254.
110. Hermine O, Dine G, Genty V, et al. Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. Biochimie. 2015;119:1-5.
111. Lio D, Balistreri CR, Colonna-Romano G, et al. Association between the MHC class I gene HFE polymorphisms and longevity: a study in Sicilian population. Genes Immun. 2002;3(1):20-24.
112. Balistreri CR, Candore G, Almasio P, et al. Analysis of hemochromatosis gene mutations in the Sicilian population: implications for survival and longevity. Arch Gerontol Geriatr Suppl. 2002;8:35-42.
113. Carru C, Pes GM, Deiana L, et al. Association between the HFE mutations and longevity: a study in Sardinian population. Mech Ageing Dev. 2003;124(4):529-532.
114. Bardou-Jacquet E, Morcet J, Manet G, et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol. 2015;62(3):682-689.
115. Cippa PE, Krayenbuehl PA. Increased height in HFE hemochromatosis. N Engl J Med. 2013;369(8):785-786.
116. Yeap BB, Beilin J, Shi Z, et al. The C282Y polymorphism of the hereditary hemochromatosis gene is associated with increased sex hormone-binding globulin and normal testosterone levels in men. J Endocrinol Invest. 2010;33(8):544-548.
117. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335(24):1799-1805.
118. Pankow JS, Boerwinkle E, Adams PC, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res. 2008;152(1):3-10.
119. Adams PC, Pankow J, Barton JC, et al. Hfe C282y Homozygosity Is Associated with Lower Total and Ldl Cholesterol: The Hemochromatosis and Iron Overload Screening (Heirs) Study. Hepatology. 2008; 48(4):437a-438a.
120. Vinchi F, Muckenthaler MU, Da Silva MC, Balla G, Balla J, Jeney V. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol. 2014;5:94.
121. Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA. 1994;272(3):231-233.
122. Sullivan JL, Zacharski LR. Hereditary haemochromatosis and the hypothesis that iron depletion protects against ischemic heart disease. Eur J Clin Invest. 2001;31(5):375-377.
123. Munoz-Bravo C, Gutierrez-Bedmar M, Gomez-Aracena J, Garcia-Rodriguez A, Navajas JF. Iron: protector or risk factor for cardiovascular disease? Still controversial. Nutrients. 2013;5(7):2384-2404.
124. Sullivan JL. Do Hemochromatosis Mutations Protect Against Iron-Mediated Atherogenesis? Circ-Cardiovasc Gene. 2009;2(6):652-657.
125. Correia AP, Pinto JP, Dias V, Mascarenhas C, Almeida S, Porto G. CAT53 and HFE alleles in Alzheimer's disease: a putative protective role of the C282Y HFE mutation. Neurosci Lett. 2009;457(3):129-132.
126. Lin M, Zhao L, Fan J, et al. Association between HFE polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis of 22 studies including 4,365 cases and 8,652 controls. Mol Biol Rep. 2012;39(3):3089-3095.
127. Li M, Wang L, Wang W, Qi XL, Tang ZY. Mutations in the HFE gene and sporadic amyotrophic lateral sclerosis risk: a meta-analysis of observational studies. Braz J Med Biol Res. 2014;47(3):215-222.
128. Xia J, Xu H, Jiang H, Xie J. The association between the C282Y and H63D polymorphisms of HFE gene and the risk of Parkinson's disease: A meta-analysis. Neurosci Lett. 2015;595:99-103.
129. Mura C, Raguenes O, Scotet V, Jacolot S, Mercier AY, Ferec C. A 6-year survey of HFE gene test for hemochromatosis diagnosis. Genet Med. 2005;7(1):68-73.